Clinical trial
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1)
NCT04263480 is registered in ClinicalTrials.gov with Christian Buske as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1)
- Lead sponsor
- Christian Buske
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 18, 2021
- Completion date
- May 31, 2028
- Enrollment
- 99 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.